PDCD1 and cancer: Peripheral blood samples from 26 patients enrolled in the Cancer Immunotherapy Trials Network CITN-09 clinical trial (ClinicalTrials.gov NCT02267603) were included with 1–4 PBMC samples obtained before and/or on anti-PD1 therapy (Supplemental Table 2).